02.04.20
AGC Biologics, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Trefoil Therapeutics, have signed a manufacturing contract to supply their lead compound TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue.
Trefoil Therapeutics selected AGC Biologics for their technical expertise and proven abilities in cGMP manufacture of protein-based therapeutics from pre-clinical to commercial production, after a three-month selection process.
"AGC Biologics' extensive experience in cGMP manufacturing makes them an ideal company to help us move TTHX1114 forward,” said David Eveleth, chief executive officer, Trefoil Therapeutics. “We believe our engineered FGF-1, which is expected to enter clinical trials during 2020 in an intracameral formulation for the treatment of corneal endothelial dystrophies, has the potential to make a substantial difference in patients' lives."
Patricio Massera, chief executive officer, AGC Biologics, said, "AGC Biologics is delighted to assist Trefoil Therapeutics with the production of this life changing product. Our teams will work together in an open and collaborative manner and we are excited about the project's potential."
AGC Biologic's global manufacturing footprint includes a cGMP-compliant facility in Heidelberg, Germany, which will begin manufacturing TTHX1114 in the coming months.
Trefoil Therapeutics selected AGC Biologics for their technical expertise and proven abilities in cGMP manufacture of protein-based therapeutics from pre-clinical to commercial production, after a three-month selection process.
"AGC Biologics' extensive experience in cGMP manufacturing makes them an ideal company to help us move TTHX1114 forward,” said David Eveleth, chief executive officer, Trefoil Therapeutics. “We believe our engineered FGF-1, which is expected to enter clinical trials during 2020 in an intracameral formulation for the treatment of corneal endothelial dystrophies, has the potential to make a substantial difference in patients' lives."
Patricio Massera, chief executive officer, AGC Biologics, said, "AGC Biologics is delighted to assist Trefoil Therapeutics with the production of this life changing product. Our teams will work together in an open and collaborative manner and we are excited about the project's potential."
AGC Biologic's global manufacturing footprint includes a cGMP-compliant facility in Heidelberg, Germany, which will begin manufacturing TTHX1114 in the coming months.